Last reviewed · How we verify
new formulations of 611
new formulations of 611 is a Small molecule drug developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | new formulations of 611 |
|---|---|
| Sponsor | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- new formulations of 611 CI brief — competitive landscape report
- new formulations of 611 updates RSS · CI watch RSS
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. portfolio CI
Frequently asked questions about new formulations of 611
What is new formulations of 611?
new formulations of 611 is a Small molecule drug developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd..
Who makes new formulations of 611?
new formulations of 611 is developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (see full Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. pipeline at /company/sunshine-guojian-pharmaceutical-shanghai-co-ltd).
What development phase is new formulations of 611 in?
new formulations of 611 is in Phase 1.